drugset / Trial / NCT07515924
Oral Gallium Maltolate for Recurrent Glioblastoma
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 0 investigational study to assess the central nervous system penetration and tumoral concentration of gallium in patients with recurrent glioblastoma administered with preoperative gallium maltolate.
Timeline
- Start
- 2026-06
- Primary completion
- 2027-09
- Completion
- 2027-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gallium maltolate | Small molecule | 2500 mg | Oral |